[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574825":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":21,"centralContacts":30,"locations":36,"responsibleParty":228,"collaborators":21,"id":230,"slug":231,"hasResults":232,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":232,"sex":238,"minAge":239,"maxAge":21,"enrollmentInfo":240,"targetDuration":21,"studyType":243,"phases":244,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":39,"whyStopped":21,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":263},{"fullName":5,"class":6},"Bayer","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BAY 3547926","EXPERIMENTAL","actinium-225 labeled antibody conjugate",[13,14,15],"Drug: BAY 3547926","Drug: BAY 3547922","Drug: BAY 3713391",[17,22,26],{"type":18,"name":9,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","antibody conjugate with actinium-225 label",[9],null,{"type":18,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"BAY 3547922","antibody conjugate without actinium-225 label as preinjection",[9],{"type":18,"name":27,"description":28,"armGroupLabels":29,"otherNames":21},"BAY 3713391","Radioactive imaging agent - optional preinjection",[9],[31],{"name":32,"role":33,"phone":34,"phoneExt":21,"email":35},"Bayer Clinical Trials Contact","CONTACT","(+)1-888-84 22937","clinical-trials-contact@bayer.com",[37,54,63,74,83,92,103,112,117,125,137,148,157,168,179,187,194,205,210,219],{"facility":38,"status":39,"city":38,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Dothan","RECRUITING","Alabama","36303","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-85.39049,31.22323,{"lat":48,"lon":47},[51],{"name":21,"role":33,"phone":21,"phoneExt":52,"email":53},"+13347929500","jlove@alocentclinical.com",{"facility":55,"status":39,"city":55,"state":56,"zip":57,"country":42,"countryCode":43,"cosmosGeoPoint":58,"geoPoint":62,"contacts":21},"Duarte","California","91010",{"type":45,"coordinates":59},[60,61],-117.97729,34.13945,{"lat":61,"lon":60},{"facility":64,"status":39,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":73,"contacts":21},"Edegem","Antwerp","2650","Belgium","BE",{"type":45,"coordinates":70},[71,72],4.44504,51.15662,{"lat":72,"lon":71},{"facility":75,"status":39,"city":75,"state":76,"zip":77,"country":67,"countryCode":68,"cosmosGeoPoint":78,"geoPoint":82,"contacts":21},"Leuven","Flemish Brabant","3000",{"type":45,"coordinates":79},[80,81],4.70093,50.87959,{"lat":81,"lon":80},{"facility":84,"status":39,"city":84,"state":85,"zip":86,"country":67,"countryCode":68,"cosmosGeoPoint":87,"geoPoint":91,"contacts":21},"Kortrijk","West Flanders","8500",{"type":45,"coordinates":88},[89,90],3.26487,50.82803,{"lat":90,"lon":89},{"facility":93,"status":39,"city":93,"state":94,"zip":95,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":102,"contacts":21},"Toronto","Ontario","M5G 2C4","Canada","CA",{"type":45,"coordinates":99},[100,101],-79.39864,43.70643,{"lat":101,"lon":100},{"facility":104,"status":39,"city":104,"state":105,"zip":106,"country":96,"countryCode":97,"cosmosGeoPoint":107,"geoPoint":111,"contacts":21},"Montreal","Quebec","H2X 0C1",{"type":45,"coordinates":108},[109,110],-73.58781,45.50884,{"lat":110,"lon":109},{"facility":104,"status":39,"city":104,"state":105,"zip":113,"country":96,"countryCode":97,"cosmosGeoPoint":114,"geoPoint":116,"contacts":21},"H4A 3J1",{"type":45,"coordinates":115},[109,110],{"lat":110,"lon":109},{"facility":118,"status":39,"city":118,"state":105,"zip":119,"country":96,"countryCode":97,"cosmosGeoPoint":120,"geoPoint":124,"contacts":21},"Sherbrooke","J1H 5N4",{"type":45,"coordinates":121},[122,123],-71.89908,45.40008,{"lat":123,"lon":122},{"facility":126,"status":39,"city":127,"state":128,"zip":129,"country":130,"countryCode":131,"cosmosGeoPoint":132,"geoPoint":136,"contacts":21},"Xuhui District","Xuhui","Shanghai Municipality","200032","China","CN",{"type":45,"coordinates":133},[134,135],121.44709,31.19594,{"lat":135,"lon":134},{"facility":138,"status":39,"city":138,"state":139,"zip":140,"country":141,"countryCode":142,"cosmosGeoPoint":143,"geoPoint":147,"contacts":21},"Tampere","Pirkanmaa","33520","Finland","FI",{"type":45,"coordinates":144},[145,146],23.78712,61.49911,{"lat":146,"lon":145},{"facility":149,"status":39,"city":149,"state":150,"zip":151,"country":141,"countryCode":142,"cosmosGeoPoint":152,"geoPoint":156,"contacts":21},"Turku","Southwest Finland","20540",{"type":45,"coordinates":153},[154,155],22.26869,60.45148,{"lat":155,"lon":154},{"facility":158,"status":39,"city":158,"state":159,"zip":160,"country":161,"countryCode":162,"cosmosGeoPoint":163,"geoPoint":167,"contacts":21},"Montpellier","Occitanie","34298","France","FR",{"type":45,"coordinates":164},[165,166],3.87635,43.61093,{"lat":166,"lon":165},{"facility":169,"status":39,"city":169,"state":170,"zip":171,"country":172,"countryCode":173,"cosmosGeoPoint":174,"geoPoint":178,"contacts":21},"L'Hospitalet de Llobregat","Barcelona","08908","Spain","ES",{"type":45,"coordinates":175},[176,177],2.10028,41.35967,{"lat":177,"lon":176},{"facility":180,"status":39,"city":180,"state":21,"zip":181,"country":172,"countryCode":173,"cosmosGeoPoint":182,"geoPoint":186,"contacts":21},"Madrid","28050",{"type":45,"coordinates":183},[184,185],-3.70256,40.4165,{"lat":185,"lon":184},{"facility":188,"status":39,"city":188,"state":21,"zip":21,"country":172,"countryCode":173,"cosmosGeoPoint":189,"geoPoint":193,"contacts":21},"Pamplona",{"type":45,"coordinates":190},[191,192],-1.64323,42.81687,{"lat":192,"lon":191},{"facility":195,"status":39,"city":195,"state":196,"zip":197,"country":198,"countryCode":199,"cosmosGeoPoint":200,"geoPoint":204,"contacts":21},"London","Greater London","NW3 2QG","United Kingdom","UK",{"type":45,"coordinates":201},[202,203],-0.12574,51.50853,{"lat":203,"lon":202},{"facility":195,"status":39,"city":195,"state":196,"zip":206,"country":198,"countryCode":199,"cosmosGeoPoint":207,"geoPoint":209,"contacts":21},"W12 0HS",{"type":45,"coordinates":208},[202,203],{"lat":203,"lon":202},{"facility":211,"status":39,"city":211,"state":212,"zip":213,"country":198,"countryCode":199,"cosmosGeoPoint":214,"geoPoint":218,"contacts":21},"Glasgow","Scotland","G12 0YN",{"type":45,"coordinates":215},[216,217],-4.25763,55.86515,{"lat":217,"lon":216},{"facility":220,"status":39,"city":220,"state":221,"zip":222,"country":198,"countryCode":199,"cosmosGeoPoint":223,"geoPoint":227,"contacts":21},"Sutton","Surrey","SM2 5PT",{"type":45,"coordinates":224},[225,226],-0.2,51.35,{"lat":226,"lon":225},{"type":229,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100574825","phase-1-a-first-in-human-study-to-learn-about-the-safety-of-bay-3547926-and-how-well-it-works-in-participants-with-advanced-liver-cancer-100574825",false,"NCT06764316","A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer","A Multicenter, Open Label, Non-randomized First-in-human Phase 1 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BAY 3547926 Alone, and in Combination, in Participants With Advanced Hepatocellular Carcinoma (HCC)","BANTAM-01","Inclusion Criteria:\n\n* Locally advanced or metastatic and\u002For unresectable HCC (hepatocellular carcinoma) with histological or cytological confirmation, or non-invasive diagnosis as per American Association for the Study of Liver Diseases (AASLD) criteria in participants with a confirmed diagnosis of cirrhosis.\n* Demonstrated positive centrally confirmed GPC3 expression by immunohistochemistry (IHC) on tumor sample.\n* Disease not amenable to, or progressive disease after, curative surgery and\u002For locoregional therapies of established efficacy such as resection, local ablation, chemoembolization.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.\n* At least one measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1. as assessed by local site Investigator within 28 days prior to the start of the study treatment.\n* Adequate bone marrow and organ function\n\nExclusion Criteria:\n\n* Fibrolamellar HCC, sarcomatoid HCC, and mixed hepatocellular\u002Fcholangiocarcinoma subtypes.\n* Participants with a history or clinical evidence of CNS metastases, unless they meet specific criteria\n* History of encephalopathy ≥ Grade 2 within the past 12 months\n* Clinically significant ascites","ALL","18 Years",{"count":241,"type":242},148,"ESTIMATED","INTERVENTIONAL",[245],"PHASE1","In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver cancer called advanced hepatocellular carcinoma (HCC), which has a special protein called Glypican 3 (GPC3). Researchers want to find the best dose of BAY 3547926 for people with advanced HCC and look at the way the body absorbs and distributes the drug.\n\nThe study drug, BAY 3547926, delivers a radioactive agent to cancer cells. The radioactive agent emits radiations which can damage the cancer cells and cause them to die. These radiations travel a small distance, so are expected to cause little damage to surrounding healthy tissues. This is the first study of BAY 3547926 in humans.\n\nParticipants will take part in one of the 4 different parts of the study. In Part 1, participants will receive different doses of BAY 3547926 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3547926 alone in Part 2 or with other treatments in Parts 3 and 4 of the study.\n\nDuring the study, the doctors and their study team will do health check-ups, take pictures (scans) of the body, collect blood and urine samples, and ask participants questions about how they are feeling and what health problems they are having.",[248],"Hepatocellular Carcinoma",[250,251,252,253],"Hepatocellular carcinoma (HCC)","Locally advanced HCC","Metastatic HCC","Unresectable HCC","2026-06-29",{"date":256,"type":257},"2026-06-30","ACTUAL",{"date":259,"type":257},"2025-02-28",{"date":261,"type":242},"2031-08-31",{"name":5,"class":6},20]